CCL2 promoter hypomethylation is associated with gout risk in Chinese Han male population
Copyright © 2017 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved..
OBJECTIVES: C-C motif chemokine ligand 2 (CCL2) encodes a chemokine which amplifies and maintains inflammation through chemokine-cytokine networks. Gout is a type of painful inflammation arthritis in response to the deposition of monosodium urate (MSU) crystals in joints. The purpose of this study was to figure out the role of CCL2 promoter methylation in gout.
METHODS: A quantitative methylation-specific polymerase chain reaction (qMSP) was used to measure CCL2 promoter methylation in 93 gout patients and 101 healthy controls, respectively. All participants were Chinese Han males. The percent of methylated reference (PMR) was used to evaluate methylation level of each sample.
RESULTS: In the current study, we have found that CCL2 promoter methylation was significantly lower in gout than in healthy controls (24.95% versus 42.68%, P<0.001). CCL2 promoter hypermethylation was considered as a risk factor of gout [OR (95% CI)=3.59E-04 (5.67E-06, 0.023), P=1.79E-04]. Receiver operating characteristic (ROC) curve analysis showed there was a significant diagnostic value of CCL2 hypomethylation for gout (AUC=0.763, 95% CI=0.695-0.830, sensitivity=0.644, specificity=0.849).
CONCLUSIONS: CCL2 promoter hypomethylation in peripheral blood could be a potential biomarker for the diagnosis of gout in Chinese Han males.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:190 |
|---|---|
| Enthalten in: |
Immunology letters - 190(2017) vom: 30. Okt., Seite 15-19 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Bin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
C-C motif chemokine ligand 2 |
|---|
| Anmerkungen: |
Date Completed 12.07.2018 Date Revised 20.07.2018 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.imlet.2017.06.011 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM273665588 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM273665588 | ||
| 003 | DE-627 | ||
| 005 | 20231225001742.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.imlet.2017.06.011 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0912.xml |
| 035 | |a (DE-627)NLM273665588 | ||
| 035 | |a (NLM)28690186 | ||
| 035 | |a (PII)S0165-2478(17)30168-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Bin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CCL2 promoter hypomethylation is associated with gout risk in Chinese Han male population |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.07.2018 | ||
| 500 | |a Date Revised 20.07.2018 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2017 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a OBJECTIVES: C-C motif chemokine ligand 2 (CCL2) encodes a chemokine which amplifies and maintains inflammation through chemokine-cytokine networks. Gout is a type of painful inflammation arthritis in response to the deposition of monosodium urate (MSU) crystals in joints. The purpose of this study was to figure out the role of CCL2 promoter methylation in gout | ||
| 520 | |a METHODS: A quantitative methylation-specific polymerase chain reaction (qMSP) was used to measure CCL2 promoter methylation in 93 gout patients and 101 healthy controls, respectively. All participants were Chinese Han males. The percent of methylated reference (PMR) was used to evaluate methylation level of each sample | ||
| 520 | |a RESULTS: In the current study, we have found that CCL2 promoter methylation was significantly lower in gout than in healthy controls (24.95% versus 42.68%, P<0.001). CCL2 promoter hypermethylation was considered as a risk factor of gout [OR (95% CI)=3.59E-04 (5.67E-06, 0.023), P=1.79E-04]. Receiver operating characteristic (ROC) curve analysis showed there was a significant diagnostic value of CCL2 hypomethylation for gout (AUC=0.763, 95% CI=0.695-0.830, sensitivity=0.644, specificity=0.849) | ||
| 520 | |a CONCLUSIONS: CCL2 promoter hypomethylation in peripheral blood could be a potential biomarker for the diagnosis of gout in Chinese Han males | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a C-C motif chemokine ligand 2 | |
| 650 | 4 | |a Diagnosis | |
| 650 | 4 | |a Gout | |
| 650 | 4 | |a Male | |
| 650 | 4 | |a Promoter methylation | |
| 650 | 7 | |a CCL2 protein, human |2 NLM | |
| 650 | 7 | |a Chemokine CCL2 |2 NLM | |
| 700 | 1 | |a Chen, Xiaoying |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Yuting |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhong, Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Cong |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Haochang |e verfasserin |4 aut | |
| 700 | 1 | |a Duan, Shiwei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Immunology letters |d 1983 |g 190(2017) vom: 30. Okt., Seite 15-19 |w (DE-627)NLM012603953 |x 1879-0542 |7 nnns |
| 773 | 1 | 8 | |g volume:190 |g year:2017 |g day:30 |g month:10 |g pages:15-19 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.imlet.2017.06.011 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 190 |j 2017 |b 30 |c 10 |h 15-19 | ||